AQR Capital Management LLC Acquires 750 Shares of Catalent, Inc. (NYSE:CTLT)

AQR Capital Management LLC increased its holdings in Catalent, Inc. (NYSE:CTLT) by 7.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,675 shares of the company’s stock after acquiring an additional 750 shares during the period. AQR Capital Management LLC’s holdings in Catalent were worth $600,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in CTLT. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Catalent in the second quarter worth approximately $42,000. Mather Group LLC. purchased a new position in Catalent during the 1st quarter worth $52,000. Longfellow Investment Management Co. LLC grew its stake in shares of Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares during the last quarter. Finally, Sound Income Strategies LLC lifted its position in shares of Catalent by 4,466.7% during the first quarter. Sound Income Strategies LLC now owns 1,370 shares of the company’s stock valued at $77,000 after purchasing an additional 1,340 shares in the last quarter.

Catalent Price Performance

NYSE CTLT opened at $60.65 on Tuesday. The company has a market cap of $10.98 billion, a PE ratio of -9.94, a price-to-earnings-growth ratio of 2.14 and a beta of 1.15. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. The firm’s 50-day simple moving average is $60.03 and its two-hundred day simple moving average is $57.65. Catalent, Inc. has a 52 week low of $31.80 and a 52 week high of $61.20.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Thursday, August 29th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The company had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.23 billion. Research analysts predict that Catalent, Inc. will post 0.95 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the transaction, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the transaction, the senior vice president now owns 39,635 shares in the company, valued at $2,360,264.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,410 shares of company stock worth $732,680 in the last quarter. 0.31% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

CTLT has been the subject of several analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Barclays boosted their price target on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, June 28th. StockNews.com started coverage on shares of Catalent in a report on Saturday. They set a “hold” rating for the company. Finally, Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Nine investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $59.83.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.